The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results
David A. Sallman
202062nd ASH Annual Meeting and Exposition30 citations
Topics & Concepts
AzacitidineMedicinePhase (matter)AntibodyClass (philosophy)Internal medicineCD47ImmunologyComputer scienceArtificial intelligenceChemistryBiologyGeneticsOrganic chemistryGeneDNA methylationGene expressionPhagocytosis and Immune RegulationRNA Interference and Gene DeliveryCAR-T cell therapy research